Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016
- PMID: 31160156
- DOI: 10.1016/j.drugpo.2019.05.014
Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016
Abstract
Background: Prisoners and other high-risk patients who show a sustained virological response (SVR) after treatment for hepatitis C virus (HCV) can become reinfected. We aimed to calculate the rate of HCV reinfection in a large cohort of inmates with SVR and to determine factors that predict reinfection.
Methods: We included all inmates treated for hepatitis C in Catalonia (Spain) from January 2002 to December 2016 who achieved SVR and in whom viral load was subsequently determined. The incidence rate was calculated per 100 person-years (100 py) of follow up. Risk factors associated with reinfection were evaluated by bivariate log-rank test and multivariate Cox regression. Hazard ratio (HR) and their 95% confidence intervals (CI) were calculated.
Results: 602 patients were included, with a mean age of 37.9 years: 95% were men, 74.1% had a history of intravenous drug use (IDU) and 28.7% were HIV-infected. Patients were followed for a total of 2154.9 years (average 3.58 ± 3.1 years). 63 (10.5%) had HCV reinfection. 41 (65.1%) presented different genotype/subgenotype, 8 the initial genotype/subgenotype, and in 14 (22.2%) the genotype could not be determined. Of the 21 reinfected patients who were interviewed, 20 (95.2%) reported IDU after antiviral treatment, and 7 (33.3%) during treatment. The overall incidence of reinfection was 2.9 cases per 100 py. All reinfections occurred in patients with IDU history. At multivariate level, HIV infection was associated with reinfection (HR = 3.03; CI:1.82-5.04).
Conclusion: In HIV-infected inmates with IDU history, the rate of reinfection of HCV post-SVR is very high. Prisons play a key role in the detection and treatment of infection and reinfection by HCV and in the post-treatment monitoring in these patients, which should be combined with counseling and the optimization of the harm reduction programs. Effective control of these vulnerable groups favours the elimination of the HCV infection.
Keywords: Chronic hepatitis C; Incidence; Prisons; RNA virus infection; Risk behaviors.
Copyright © 2019. Published by Elsevier B.V.
Comment in
-
Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments.Int J Drug Policy. 2020 Mar;77:102597. doi: 10.1016/j.drugpo.2019.11.005. Epub 2020 Jan 15. Int J Drug Policy. 2020. PMID: 31952886 No abstract available.
Similar articles
-
Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.J Hepatol. 2013 Jul;59(1):45-51. doi: 10.1016/j.jhep.2013.03.008. Epub 2013 Mar 22. J Hepatol. 2013. PMID: 23523577
-
High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.Int J Drug Policy. 2019 Oct;72:181-188. doi: 10.1016/j.drugpo.2019.06.016. Epub 2019 Jun 26. Int J Drug Policy. 2019. PMID: 31253391
-
Hepatitis C reinfection after sustained virological response.J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11. J Hepatol. 2016. PMID: 26780289 Clinical Trial.
-
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.Liver Int. 2023 Dec;43(12):2625-2644. doi: 10.1111/liv.15705. Epub 2023 Oct 10. Liver Int. 2023. PMID: 37817387
-
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.Lancet HIV. 2022 Jun;9(6):e414-e427. doi: 10.1016/S2352-3018(22)00077-7. Lancet HIV. 2022. PMID: 35659336
Cited by
-
Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.Rev Esp Sanid Penit. 2020 May-Aug;22(2):66-74. doi: 10.18176/resp.00012. Epub 2020 Jul 20. Rev Esp Sanid Penit. 2020. PMID: 32697276 Free PMC article.
-
The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.Liver Int. 2021 Oct;41(10):2341-2357. doi: 10.1111/liv.14976. Epub 2021 Jun 16. Liver Int. 2021. PMID: 34051040 Free PMC article.
-
Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan.Open Forum Infect Dis. 2020 Jul 17;7(8):ofaa301. doi: 10.1093/ofid/ofaa301. eCollection 2020 Aug. Open Forum Infect Dis. 2020. PMID: 32818142 Free PMC article.
-
Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study).Sci Rep. 2023 Sep 25;13(1):16012. doi: 10.1038/s41598-023-42701-1. Sci Rep. 2023. PMID: 37749145 Free PMC article.
-
Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting.Harm Reduct J. 2024 Apr 27;21(1):88. doi: 10.1186/s12954-024-01009-7. Harm Reduct J. 2024. PMID: 38678266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical